Join
Live feed
·
PRReleasevia Quantisnow
Kazia Therapeutics Limited logo

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

ByQuantisnow·Wall Street's wire, on your screen.
KZIA· Kazia Therapeutics Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KZIA (Kazia Therapeutics Limited) and more on Quantisnow.